Board/Management Information • Jan 28, 2014
Board/Management Information
Open in ViewerOpens in native device viewer
January 28, 2014
In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transactions under ISIN DK0060336014, Novozymes B shares under the symbol NZYM B.
| Name | Novo A/S | ||
|---|---|---|---|
| Relation/category of close relation | Novo A/S is closely related to the chairman of |
||
| Novozymes' board of directors, Henrik Gürtler | |||
| Trading date | January 27, 2014 | ||
| Market | Nasdaq OMX Copenhagen A/S | ||
| Character of transaction | Sale of shares | ||
| Volume of transaction buy(+)/ sell (-) | -60,000 | ||
| Value of transaction (DKK) | 13,588,878.00 DKK | ||
This sale has been completed according to earlier communicated intention by Novo A/S to keep its relative holding of Novozymes B shares at the level it held prior to Novozymes' cancellation of B shares on 5 April 2013 (Company announcement no. 50, August, 2011).
| Thomas Bomhoff (DK) | +45 3077 1226 | [email protected] |
|---|---|---|
| Klaus Sindahl (DK) | +45 5363 0134 | [email protected] |
| Martin Riise (USA) | +1 919 649 2565 | [email protected] |
| Rene Tronborg (DK) | +45 3077 2274 | [email protected] |
|---|---|---|
| Frederik Bjoerndal (Europe) | +45 3077 0236 | [email protected] |
| Paige Donnelly (USA) | +1 919 218 4501 | [email protected] |
| Meng Lian (China) | +86 136 9923 1164 | [email protected] |
| Henrique Pellini (Brazil) | +55 41 9288 0282 | [email protected] |
| Poonam Kapila (India) | +91 991 082 2339 | [email protected] |
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.